Anuh Pharma (506260) Q4 05/06 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 05/06 earnings summary
23 Oct, 2026Executive summary
FY06 net sales and operating income rose 49.14% YoY to Rs771.2m; PBT increased 41.28% to Rs101.3m and PAT rose 41.57% to Rs66.42m.
The new factory was completed and came on stream during the current year; management expected growth in export and domestic sales.
Financial highlights
Gross sales and operating income were Rs809.1m versus Rs539.6m; net sales and operating income were Rs771.2m versus Rs517.0m.
PAT was Rs66.42m versus Rs46.61m; total income was Rs798.1m versus Rs539.2m.
Other income was Rs26.95m versus Rs22.21m, including Rs9.97m profit on investment sales and Rs10.95m export incentives.
Proposed final dividend was Rs6 per Rs5 face-value share; bonus shares allotted to eligible holders also qualified for the dividend.
Outlook and guidance
With the new factory operational, directors expected good growth in exports and local sales turnover during the current year.
Management expected good export growth; exports reached Rs374.22m in FY06 versus Rs261.5m in FY05, up 43.1%.
Latest events from Anuh Pharma
- Sales and exports grew as the new Tarapur API facility came on stream.506260
Q4 06/07 - Profit rose despite weaker sales; a 1:1 bonus issue and 50% dividend were proposed.506260Q4 97/98
- Profit rose despite falling sales, with export growth and deposit-compliance concerns.506260Q4 98/99
- Sales rose 50% and exports climbed to Rs 99.03m as PAT reached Rs 24.34m.506260Q4 99/00
- PAT rose to ₹39.80m as exports grew and Tarapur capacity expansion began.506260Q4 01/02
- Sales grew 11.6%, exports surged, and PAT softened; dividend rose to ₹12.50/share.506260Q4 02/03
- Sales rose 50.1%, exports 46.5%, and PAT reached Rs 60.3m in FY04.506260Q4 03/04
- Profit fell amid export weakness; a new factory targets ~70% more capacity.506260Q4 04/05
- FY08 sales rose 35%, PAT grew 13.29%, and 150 MT of capacity was planned.506260Q4 07/08